.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP53_OmbitasvirParitaprevirAndRitonav.OmbitasvirParitaprevirAndRitonav .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP53_OmbitasvirParitaprevirAndRitonav.OmbitasvirParitaprevirAndRitonav| name: | OmbitasvirParitaprevirAndRitonavir |
| ATC code: | J05AP53 | route: | oral |
| n-compartments | 2 |
Ombitasvir, paritaprevir, and ritonavir is a fixed-dose combination antiviral medication used in the treatment of chronic hepatitis C virus (HCV) infection. Ombitasvir is an NS5A inhibitor, paritaprevir is an NS3/4A protease inhibitor, and ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism of paritaprevir. This combination is approved for use in many countries and was commonly marketed as part of the Viekira Pak regimen.
Pharmacokinetic parameters in healthy adult volunteers after oral administration of the co-formulated combination under fed conditions.
Mensing, S, et al., & Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS journal 18(1) 270–280. DOI:10.1208/s12248-015-9846-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26597291
Gopalakrishnan, SM, et al., & Menon, RM (2017). Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical pharmacokinetics 56(1) 1–10. DOI:10.1007/s40262-016-0423-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27314261
Minaei, AA, & Kowdley, KV (2015). ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert opinion on pharmacotherapy 16(6) 929–937. DOI:10.1517/14656566.2015.1024653 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25800085